Clearside Biomedical Community
NasdaqGM:CLSD Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 6 Analysts
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Key Takeaways FDA alignment on CLS-AX for wet AMD and Phase 2b outcomes may boost revenues and market leadership upon approval. Global partnerships and SCS technology expansions could enhance international market presence and revenue streams.
View narrativeUS$5.83
FV
85.2% undervalued intrinsic discount129.65%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Updated narrative